I-Mab expected to post a loss of 28 cents a share - Earnings Preview

NovaBridge Biosciences

15/08/2023 14:33

* I-Mab  IMAB.OQ   IMAB.O  is expected to report results on
August
17.
    * 
    * ​Refinitiv's mean analyst estimate for I-Mab is for a loss
of 28
cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for I-Mab is
$25​,
above​ its last closing price of $2.55. ​​​

This summary was machine generated August 15 at 13:33 GMT.  All
figures in US dollars  unless otherwise stated